News

Home>News
News2020-07-17T11:41:26-04:00
Mar 22021

Halberd’s 2nd Proprietary Antibody Against SARS-COV-2 Spike Protein Demonstrates Neutralizing Affinity 20 Times Greater

March 2nd, 2021|Categories: Featured, Investor News, News|Tags: , , , , , , |

Jackson Center, PA, March 2, 2021 – Halberd Corp. (OTC PINK:HALB) has recently produced a proprietary monoclonal antibody that has at least 20 times greater neutralizing affinity than their original antibody against the SARS-COV 2 Spike protein. Dr. Reyes, Halberd’s Chief Technical Officer, indicated, “Our latest results indicate increased specificity of our second antibody, which can be used as a stand-alone or in combination with other antibodies for the overall optimum management of COVID-19.  Based ...

Feb 162021

Halberd Collaborates With GreenBioAZ, Inc. For the Development of Its Patent Pending Radio Frequency Technology to Eliminate Disease Pathogens

February 16th, 2021|Categories: Featured, Investor News, News|Tags: , , , , , , |

Jackson Center, PA, February 16, 2021 – Halberd Corp. (OTC PINK:HALB) has engaged GreenBioAZ, Inc. to conduct laboratory testing of Halberd’s patent pending Radio Frequency (RF) extracorporeal treatment to eliminate infectious disease pathogens.  The methodology entails treating bodily fluids with an Antibody-Metallic Moiety Conjugate (AMMC) which targets a specific pathogen such as SARS-CoV-2 during extracorporeally exposing bodily fluids to a specific Radio Frequency wavelength.  This will permit the established frequency of the electromagnetic wave being ...

Feb 12021

Halberd Corporation’s CEO Interviewed on The Stock Day Podcast and on MoneyTV

February 1st, 2021|Categories: Featured, Investor News, News|Tags: , , , , |

Jackson Center, PA, February 1, 2021 – Halberd Corporation’s (OTC PINK:HALB) Chairman, President & CEO, William A. Hartman, was interviewed recently on The Stock Day Podcast, hosted by Everett Jolly, and on MoneyTV, hosted by Don Baillargeon.  In each interview, Mr. Hartman reviewed the company’s progress on developing SARS-CoV-2 spike protein antibodies which could be used in diagnosing, preventing and treating COVID-19.  To view the entire MoneyTV Interview, click here. Hartman commented on Halberd’s latest ...

Jan 282021

Halberd Corporation Discusses Qualitative & Quantitative Diagnostic Methodology for Detecting COVID-19 Antibodies and Antigens with The Stock Day Podcast

January 28th, 2021|Categories: Featured, Investor News, News|Tags: , , , |

Halberd Corporation Discusses Qualitative & Quantitative Diagnostic Methodology for Detecting COVID-19 Antibodies and Antigens with The Stock Day Podcast   Phoenix, AZ January 28th, 2021 (Newsfile Corp.) -- The Stock Day Podcast welcomed Halberd Corporation (OTC Pink: HALB) ("the Company"), a company with a patented extracorporeal treatment applicable to many hard-to-cure blood-borne and neurological diseases, including COVID-19, other viruses, and PTSD.  President and CEO of the Company, William A. Hartman, joined Stock Day host Everett ...

Jan 142021

Halberd Corp. Develops Medication to Boost Immune System Against SARS-CoV-2 (Covid-19)

January 14th, 2021|Categories: Featured, Investor News, News|Tags: , , , , , , , |

Jackson Center, PA, January 14, 2021 – Halberd Corp. (OTC PINK: "HALB") announced the filing of a provisional patent application on a proprietary combination of nutritional supplements (melatonin, zinc and Vitamin D) combined with low dose Naltrexone designed to reduce the severity of Covid-19 symptoms.  This proprietary combination of nutritional supplements is based on numerous peer-reviewed publications (1, 2, 3, 4, 5, 6, 7) from major medical organizations indicating that each of the ingredients contributes ...

Jan 122021

Halberd Corporation’s Covid-19 Efforts Recognized in Wall Street PR News Article

January 12th, 2021|Categories: Featured, Investor News, News|Tags: , , , , , , |

Jackson Center, PA, January 12, 2021 – Halberd Corp. (OTC PINK: "HALB") was recently included alongside Novavax Inc (NASDAQ:NVAX) and Moderna Inc (NASDAQ:MRNA) in a recent Wall Street PR article on Covid-19 related stocks poised to have an impact in 2021.  Halberd was noted to be working in a different direction from the vaccine producers.  According to the article, with vaccines already receiving pushback from the public, Halberd’s prevention and symptom alleviation approach, both pre-infection ...

Go to Top